We aim to democratize health by delivering transformative medicines that are accessible to all patients in need. We develop active immunotherapies that train the body’s own immune system to fight disease.
We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of all patients and families affected by Alzheimer’s, Parkinson’s, and other chronic disease.
We envision a world where chronic disease is prophylactically eradicated.
By The Numbers
80 years ago, it was polio. Today, our epidemic is Alzheimer’s.
CHANCE YOU WILL HAVE ALZHEIMER’S
IF OVER 85 YEARS OLD
ANNUAL COST TO THE WORLD
Just as science brought us a vaccine against polio and virtually eradicated the disease worldwide, we are working to develop active immunotherapies to treat and ultimately prevent Alzheimer’s and other neurological diseases.
We aren’t your average vaccine company.
We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry’s leading long acting biologic technology. After two decades of research and over 3 billion doses commercialized on other indications, we are now developing the world’s most advanced active immunotherapy against Alzheimer’s.
July 31, 2019 -
For decades, research into Alzheimer's has made slow progress, but now a mother and daughter team think they have finally found a solution – a vaccine that could inoculate potential sufferers.Read More